primary BCMA-CAR T cells

Primary BCMA-CAR T cells are a class of chimeric antigen receptor (CAR) T-cell therapies that target the B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells in multiple myeloma. Unlike induced pluripotent stem cell (iPSC)-derived or 'off-the-shelf' allogeneic products, 'primary' CAR-T cells are typically manufactured using T cells harvested directly from a patient (autologous) or a healthy donor. The T cells are genetically modified to express a CAR that recognizes BCMA, expanded ex vivo, and then re-infused into the patient to induce targeted anti-tumor cytotoxicity. This modality has revolutionized the treatment of relapsed or refractory multiple myeloma, with several products such as idecabtagene vicleucel and ciltacabtagene autoleucel having received regulatory approval.

Other names

BCMA-targeted CAR-T cellsautologous BCMA CAR-T cellsprimary BCMA CAR T cells